KCNF1 and neoplasm: Tumor vaccines based on the KH-1 antigen have been proven to induce IgM and IgG antibodies against KH-1 and to show great safety due to low cross-reactivity with the Lex antigen, which is also expressed by neutrophilic granulocytes [16,17].